Related references
Note: Only part of the references are listed.Immune Checkpoint Inhibitors: An Introduction to the Next-Generation Cancer Immunotherapy
Lucy Lee et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial
Chih-Jian Lih et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2016)
ALK Protein Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm
Antonio Marchetti et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Decision-making impact on adjuvant chemotherapy allocation in early node-negative breast cancer with a 21-gene assay: systematic review and meta-analysis
Federico Augustovski et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Mechanisms of lapatinib resistance in HER2-driven breast cancer
Valentina D'Amato et al.
CANCER TREATMENT REVIEWS (2015)
Individualization of tamoxifen therapy: Much more than just CYP2D6 genotyping
Lisette Binkhorst et al.
CANCER TREATMENT REVIEWS (2015)
Next-Generation Sequencing to Guide Clinical Trials
Lillian L. Siu et al.
CLINICAL CANCER RESEARCH (2015)
Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
Aurelia H. M. de Vries Schultink et al.
CLINICAL PHARMACOKINETICS (2015)
Targeted therapy in HER2-positive metastatic breast cancer: a review of the literature
X. Zhu et al.
CURRENT ONCOLOGY (2015)
Diagnostic associations of gene expression signatures in prostate cancer tissue
Hao G. Nguyen et al.
CURRENT OPINION IN UROLOGY (2015)
Therapeutic management of ALK+ nonsmall cell lung cancer patients
Boris Duchemann et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine
Amanda J. Redig et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial
Ariel Lopez-Chavez et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31
Karen A. Gelmon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Stem Cell State and the Epithelial-to-Mesenchymal Transition: Implications for Cancer Therapy
Vera S. Donnenberg et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Application of Molecular Profiling in Clinical Trials for Advanced Metastatic Cancers
Shivaani Kummar et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
Funda Meric-Bernstam et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Christophe Le Tourneau et al.
LANCET ONCOLOGY (2015)
NCI-MATCH pairs tumor mutations with matching drugs
Vicki Brower
NATURE BIOTECHNOLOGY (2015)
NCI-MATCH trial pushes cancer umbrella trial, paradigm
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Oncotype DX® colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: A review of the evidence
Y. Nancy You et al.
SURGICAL ONCOLOGY-OXFORD (2015)
Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy
Anna Niezgoda et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Application of Molecular Profiling in Clinical Trials for Advanced Metastatic Cancers
Shivaani Kummar et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
Funda Meric-Bernstam et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options
Hanfang Jiang et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2015)
Combination therapies to inhibit the RAF/MEK/ERK pathway in melanoma: we are not done yet
Grant A. McArthur
FRONTIERS IN ONCOLOGY (2015)
Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
Hidemi Kawajiri et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
Trastuzumab emtansine: mechanisms of action and drug resistance
Mark Barok et al.
BREAST CANCER RESEARCH (2014)
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
J-Y Douillard et al.
BRITISH JOURNAL OF CANCER (2014)
Prospective Study of the Effect of the 21-Gene Assay on Adjuvant Clinical Decision-Making in Japanese Women With Estrogen Receptor-Positive, Node-Negative, and Node-Positive Breast Cancer
Hideko Yamauchi et al.
CLINICAL BREAST CANCER (2014)
CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
M. A. Province et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Clinical Implementation of Germ Line Cancer Pharmacogenetic Variants During the Next-Generation Sequencing Era
N. K. Gillis et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process
Kelly E. Caudle et al.
CURRENT DRUG METABOLISM (2014)
Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens
Colin C. Pritchard et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2014)
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2014)
Discovery and saturation analysis of cancer genes across 21 tumour types
Michael S. Lawrence et al.
NATURE (2014)
Assessing the clinical utility of cancer genomic and proteomic data across tumor types
Yuan Yuan et al.
NATURE BIOTECHNOLOGY (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer REPLY
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Benjamin J. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and copanion diagnostics
Saumya Pant et al.
FRONTIERS IN ONCOLOGY (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
Matthew P. Goetz et al.
CLINICAL CANCER RESEARCH (2013)
Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing
K. E. Caudle et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update
M. V. Relling et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Afatinib: First Global Approval
Rosselle T. Dungo et al.
DRUGS (2013)
Genomics-Driven Oncology: Framework for an Emerging Paradigm
Levi A. Garraway
JOURNAL OF CLINICAL ONCOLOGY (2013)
Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581
Alan P. Venook et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin
Greg Yothers et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
'Basket studies' will hold intricate data for cancer drug approvals
Cassandra Willyard
NATURE MEDICINE (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?
Daniel Crona et al.
BIOMARKERS IN MEDICINE (2012)
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement
Hye Ryun Kim et al.
CANCER (2012)
Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
Johannes M. Heuckmann et al.
CLINICAL CANCER RESEARCH (2012)
Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
Alexander M. Menzies et al.
CLINICAL CANCER RESEARCH (2012)
Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
Yusuke Nakamura et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
James M. Rae et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
Meredith M. Regan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
Robert Pirker et al.
LANCET ONCOLOGY (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only
Yuki Togashi et al.
PLOS ONE (2012)
High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
Nikhil Wagle et al.
CANCER DISCOVERY (2012)
CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Hiroshi Sakamoto et al.
CANCER CELL (2011)
Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing
M. V. Relling et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Nikhil Wagle et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The HERNATA Study
Michael Andersson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
Kenneth J. O'Byrne et al.
LANCET ONCOLOGY (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
BRAF Mutations in Hairy-Cell Leukemia
Enrico Tiacci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk
Zhe-Yi Hu et al.
CLINICAL CANCER RESEARCH (2010)
Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection
Shelly S. Lo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
Kengo Takeuchi et al.
CLINICAL CANCER RESEARCH (2009)
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
A. D. Barker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
Laura E. MacConaill et al.
PLOS ONE (2009)
Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
Patrick J. Medina et al.
CLINICAL THERAPEUTICS (2008)
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study
Richard Gray et al.
LANCET (2007)
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Klarisa Rikova et al.
CELL (2007)
New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer
V. Craig Jordan
STEROIDS (2007)
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
M. M. Moasser
ONCOGENE (2007)
Impact of a Commercial Reference Laboratory Test Recurrence Score on Decision Making in Early-Stage Breast Cancer
Ruth Oratz et al.
JOURNAL OF ONCOLOGY PRACTICE (2007)
iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors
L. V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Ancestry and phannacogenetics of antileukernic drug toxicity
Shinji Kishi et al.
BLOOD (2007)
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
EGF-ERBB signalling: towards the systems level
Ami Citri et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
M Marty et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia
M Stanulla et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
F Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
UM Zanger et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm
HJ Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer
FJ Esteva et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
AD Seidman et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
